Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 2
2008 4
2009 4
2010 5
2011 7
2012 5
2013 4
2014 5
2015 8
2016 4
2017 6
2018 7
2019 8
2020 11
2021 6
2022 6
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

85 results
Results by year
Filters applied: . Clear all
Page 1
Real-world persistence with dupilumab among adults with atopic dermatitis.
Silverberg JI, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya UG, Mastey V, Zhang H, Chen Z, Chen C, Korotzer A, Sierka D, Fenton MC, Kaur M, Jalbert JJ. Silverberg JI, et al. Among authors: kuznik a. Ann Allergy Asthma Immunol. 2021 Jan;126(1):40-45. doi: 10.1016/j.anai.2020.07.026. Epub 2020 Jul 31. Ann Allergy Asthma Immunol. 2021. PMID: 32739313 Free article.
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Keeping S, Xu Y, Chen CI, Cope S, Mojebi A, Kuznik A, Konidaris G, Ayers D, Sasane M, Allen R, Huynh TM, Popoff E, Freeman M, Andria ML, Fury MG, Singh K, Stockfleth E, Challapalli A, Schmults CD. Keeping S, et al. Among authors: kuznik a. Future Oncol. 2021 Feb;17(5):611-627. doi: 10.2217/fon-2020-0823. Epub 2020 Oct 14. Future Oncol. 2021. PMID: 33052055 Free article.
Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Muszbek N, Proudfoot C, Fournier M, Chen CI, Kuznik A, Kiss Z, Gal P, Michaud K. Muszbek N, et al. Among authors: kuznik a. J Manag Care Spec Pharm. 2019 Nov;25(11):1268-1280. doi: 10.18553/jmcp.2019.25.11.1268. J Manag Care Spec Pharm. 2019. PMID: 31663465
Bisphosphonates-much more than only drugs for bone diseases.
Kuźnik A, Październiok-Holewa A, Jewula P, Kuźnik N. Kuźnik A, et al. Eur J Pharmacol. 2020 Jan 5;866:172773. doi: 10.1016/j.ejphar.2019.172773. Epub 2019 Nov 6. Eur J Pharmacol. 2020. PMID: 31705903 Review.
A step towards gadolinium-free bioresponsive MRI contrast agent.
Wyskocka-Gajda M, Przypis Ł, Olesiejuk M, Krawczyk T, Kuźnik A, Nawara K, Minoshima M, Sugihara F, Kikuchi K, Kuźnik N. Wyskocka-Gajda M, et al. Among authors: kuznik a. Eur J Med Chem. 2021 Feb 5;211:113086. doi: 10.1016/j.ejmech.2020.113086. Epub 2020 Dec 8. Eur J Med Chem. 2021. PMID: 33348236
85 results